NasdaqCM - Delayed Quote • USD
Adverum Biotechnologies, Inc. (ADVM)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:34 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -1.41 | -1.31 | -5.41 | -5.43 |
| Low Estimate | -1.91 | -1.48 | -6.01 | -6 |
| High Estimate | -1.2 | -1.2 | -4.8 | -4.9 |
| Year Ago EPS | -2.9 | -3.1 | -11.6 | -5.41 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | 3.6M | -- | 3.6M | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -3.2 | -3.29 | -3.15 | -3.37 |
| EPS Actual | -2.9 | -3.1 | -3.3 | -2.3 |
| Difference | 0.3 | 0.19 | -0.15 | 1.07 |
| Surprise % | 9.40% | 5.80% | -4.80% | 31.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.41 | -1.31 | -5.41 | -5.43 |
| 7 Days Ago | -1.41 | -1.31 | -5.41 | -5.43 |
| 30 Days Ago | -0.15 | -0.14 | -0.63 | -0.6 |
| 60 Days Ago | -0.27 | -0.22 | -0.93 | -0.87 |
| 90 Days Ago | -0.28 | -0.23 | -0.93 | -0.89 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 2 | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ADVM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 51.40% | -- | -- | 1.60% |
| Next Qtr. | 57.70% | -- | -- | 10.50% |
| Current Year | 53.40% | -- | -- | 5.20% |
| Next Year | -0.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Chardan Capital: Buy to Buy | 3/19/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 3/19/2024 |
| Maintains | Mizuho: Buy to Buy | 2/6/2024 |
| Initiated | Mizuho: Buy | 11/2/2023 |
| Reiterates | Truist Securities: Buy to Buy | 9/5/2023 |
| Upgrade | Chardan Capital: Neutral to Buy | 8/11/2023 |
Related Tickers
RGNX REGENXBIO Inc.
15.69
-2.61%
FDMT 4D Molecular Therapeutics, Inc.
25.25
+1.90%
EYPT EyePoint Pharmaceuticals, Inc.
17.65
+0.86%
AVIR Atea Pharmaceuticals, Inc.
3.7200
+0.54%
GBIO Generation Bio Co.
2.8000
+0.72%
FULC Fulcrum Therapeutics, Inc.
6.84
-3.12%
AVRO AVROBIO, Inc.
1.2000
-3.23%
ALEC Alector, Inc.
5.09
0.00%
DTIL Precision BioSciences, Inc.
9.74
-9.14%
ALVR AlloVir, Inc.
0.7502
+1.09%